TABLE 3.

Safety Through Week 24

	B/F/TAF (n = 330)	SBR (No Switch) (n = 165)
Any adverse event	210 (64)	85 (52)
Adverse events in >3% of participants
Upper respiratory tract infection	20 (6)	6 (4)
Diarrhea	11 (3)	5 (3)
Cough	9 (3)	6 (4)
Arthralgia	11 (3)	2 (1)
Bronchitis	5 (2)	7 (4)
Grade 3 or 4 adverse event	17 (5)	8 (5)
Serious adverse event	13 (4)	7 (4)
Adverse event leading to study drug discontinuation*	7 (2)	0
Treatment-related adverse event	36 (11)	0
Death	0	0
Laboratory abnormalities
Of any grade	215 (65)	111 (67)
Grade 3	24 (7)	10 (6)
Grade 4	3 (1)	0

Data are n (%).

^*Adverse events leading to study drug discontinuation in the B/F/TAF group included nightmare^† (n = 1); headache^† (n = 1); acute kidney injury (n = 1); diarrhea,^† dry mouth,^† psychomotor hyperactivity,^† agitation,^† anxiety,^† and insomnia^† (n = 1); abdominal distension^† and flatulence^† (n = 1); diarrhea^† (n = 1); and migraine^† (n = 1).

^†Reported as treatment related.